Top Markets
#1 Siren Siren +34.73%
#2 Wiki Cat Wiki Cat +29.51%
#3 Ribbita by Virtuals Ribbita by Virtuals +19.62%
#4 Bitway Bitway +19.40%
#5 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +17.06%
#6 PulseChain PulseChain +16.92%
#7 TRIA TRIA +16.38%
#8 Velvet Velvet +16.02%
#9 Cysic Cysic +15.60%
#10 The Grays Currency The Grays Currency +15.46%
Coin of the day
Siren Siren
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Synthetic Biologics, Inc. Synthetic Biologics, Inc.

Synthetic Biologics, Inc.

SYN
Rang in aandelen #30607
Synthetic Biologics, Inc. is a clinical-stage biotechnology firm focused on... Synthetic Biologics, Inc. is a clinical-stage biotechnology firm focused on creating treatments for illnesses with significant unmet medical demands. Among its leading product candidates is SYN-004, engineered to neutralize common intravenous beta-lactam antibiotics within the digestive system. This aims to safeguard the gut microbiome, prevent Clostridium difficile infections (CDI), curb the proliferation of harmful bacteria, combat antimicrobial resistance (AMR), and mitigate acute graft-versus-host-disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key asset is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, intended to address both localized gastrointestinal and systemic conditions. The company is also advancing VCN-01, a therapeutic candidate for various cancers, including pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Additional clinical-stage programs include SYN-006, targeting the prevention of aGVHD and infections from carbapenem-resistant enterococci; SYN-007, designed to avert antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for the prevention and treatment of whooping cough (pertussis); and VCN-11, another cancer therapeutic. Synthetic Biologics maintains partnerships with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis supports a Phase 1b/2a clinical trial for SYN-004. The company's main operations are based in Rockville, Maryland.
Aandeelprijs
$1.02
Laatst gesynchroniseerd: 2022-10-13
Marktkapitalisatie
$16.16M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Synthetic Biologics, Inc. (SYN)

Categorie

Healthcare
Dividendgeschiedenis van Synthetic Biologics, Inc. (SYN)
Synthetic Biologics, Inc. (aandelsymbool: SYN) heeft in totaal 0 dividenduitkeringen gedaan.
De som van alle dividenden (aangepast voor aandelensplitsingen) is: 0.00
Dividendrendement (TTM): 0
Dividendbetalingen voor Synthetic Biologics, Inc. (SYN) van 2026 tot 2026
Jaarlijkse dividendbetalingen
Jaar Dividend (aangepast voor aandelensplitsingen) Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Lijst van alle dividendbetalingen
Jaar Dividend Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendbetalingen voor vergelijkbare bedrijven of concurrenten
Bedrijf Aantal dividendbetalingen Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
29.00%
BE